Prior authorization for peptide medicines: what to prepare

Ask the insurer which exact product and indication require authorization, whether step therapy or quantity limits apply, and which form the prescriber must use. Medicare’s drug-plan rules explain these types of restrictions for Part D. Do not assume a social-media report about another plan applies to yours. A product’s FDA label and your plan’s policy answer different questions. Medicare: Drug plan rules FDA: Labeling FAQ for prescription medicines

The prescriber may need the diagnosis, relevant history, previous treatment, contraindications, and reason the requested product fits the patient. Provide accurate information and ask when the request was submitted. AHRQ advises keeping a medicine list and communicating clearly with clinicians. Do not invent a diagnosis or claim a treatment was tried when it was not; inconsistent information can delay care and undermine the clinical decision. AHRQ: Talk with your doctor

Request the authorization reference, expected response time, and the plan’s stated reason if denied. Ask whether the pharmacy can hold the prescription while review is pending and what to do if treatment continuity is at risk. Medicare describes coverage determinations and appeal steps for drug plans; other insurers use their own processes. Keep copies of letters rather than relying only on a phone summary. Medicare: Drug plan appeals

A denial may reflect missing documentation, a plan exclusion, or a clinical criterion. The prescriber should explain whether an appeal is reasonable and what alternatives exist. Avoid treating a cash-pay research-use product as a medically equivalent replacement. FDA distinguishes approved products from compounded drugs, and coverage frustration does not change the evidence for either. FDA: Compounding and the FDA Q&A

If you know a medicine often needs authorization, ask the prescriber’s office and plan what records are required before the first fill. Confirm who will submit and who will notify you of a decision. Refill authorizations may need renewal, so set a reminder before the current approval expires. A plan’s timing rules can be particularly important when stopping and restarting would disrupt care. Medicare: Drug plan rules

An appeal can explain why the patient meets criteria or why a standard option is unsuitable, but it should be grounded in the actual record. Ask the clinician to correct an error, not to tailor a diagnosis to coverage language. If the plan upholds a denial, discuss a revised medical plan and cost with the team. FDA approval, clinical judgment, and payer coverage remain separate. FDA: Understanding FDA terms